Mifepristone was not ordered to be removed from the market, and the case goes to Supreme Court.
The 5th Circuit Court of Appeals ruled that the Food and Drug Administration (FDA) improperly increased access to the abortion drug mifepristone, ordering a ban on remote prescriptions and mail orders of the drug.
Pro-life groups filed the lawsuit, claiming that the FDA improperly approved mifepristone in 2000 by not considering how dangerous the drug was for minors. The three judges ruled that it was too late to address those concerns, but rolled back the FDA’s recent allowance of mailed prescriptions of mifepristone, which was done to overcome abortion restrictions in certain states.
The Department of Justice will appeal this decision to the Supreme Court. The ban on mailed mifepristone will not go into effect until the Supreme Court justices finish their review of the case.
As the Lord Leads, Pray with Us…
- For officials in the Justice Department as they prepare to argue this case before the Supreme Court.
- For Supreme Court justices as they determine which cases they will hear in the fall term.
- For FDA officials as they evaluate the limits and restrictions on prescription drugs.
Sources: Reuters, Forbes, The Hill
